Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Elzonris (tagraxofusp-erzs) for the Treatment of BPDCN

Elzonris™ is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and paediatric patients. Image courtesy of http://www.ebi.ac.uk/

  • Elzonris
  • Elzonris
  • Elzonris

Go Top